Mr. Liang Lv has been Chairman of the Board at Huadong Medicine Co., Ltd since June 06, 2019 and serves as its General Manager. He served as Deputy General Manager of Huadong Medicine Co., Ltd since April...

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Liang Lv	Chairman & GM	14.7yrs	CN¥2.40m	Veri yok
Xinhua Bai	Chairman of Supervisory Committee	26.9yrs	Veri yok	Veri yok
Jian Huang	Independent Director	1.6yrs	CN¥65.20k	Veri yok
Yun Qin	Supervisor	18.6yrs	Veri yok	Veri yok
Wei Kang	Non-Independent Director	8yrs	CN¥30.00k	Veri yok
Liang Zhu	Non-Independent Director	5.5yrs	CN¥650.00k	Veri yok
Zhifeng Xu	Employee Supervisor	5.5yrs	Veri yok	Veri yok
Feipeng Zhu	Non-Independent Director	2.5yrs	CN¥30.00k	Veri yok
Bo Ye	Non-Independent Director	2.5yrs	CN¥30.00k	Veri yok
Xiangdong Gao	Independent Director	2.5yrs	CN¥100.00k	Veri yok
Ruwei Wang	Independent Director	2.5yrs	CN¥100.00k	Veri yok
Yang Wang	Director	1.4yrs	CN¥13.60k	Veri yok

4.0yrs

Ortalama Görev Süresi

55yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: 000963 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 4 yıldır).

Şirket Analizi ve Finansal Veri Durumu

Veri	Son Güncelleme (UTC saati)
Şirket Analizi	2024/12/23 16:17
Gün Sonu Hisse Fiyatı	2024/12/23 00:00
Kazançlar	2024/09/30
Yıllık Kazançlar	2023/12/31

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

Paket	Veri	Zaman Çerçevesi	Örnek ABD Kaynağı ^*
Şirket Finansalları	10 yıl	Gelir tablosu Nakit akış tablosu Bilanço	SEC Form 10-K SEC Form 10-Q
Analist Konsensüs Tahminleri	+3 yıl	Finansal tahminler Analist fiyat hedefleri	Analist Araştırma Raporları Blue Matrix
Piyasa Fiyatları	30 yıl	Hisse senedi fiyatları Temettüler, Bölünmeler ve Eylemler	ICE Piyasa Verileri SEC Form S-1
Sahiplik	10 yıl	En büyük hissedarlar İçeriden öğrenenlerin ticareti	SEC Form 4 SEC Form 13D
Yönetim	10 yıl	Liderlik ekibi Yönetim Kurulu	SEC Form 10-K SEC Form DEF 14A
Önemli Gelişmeler	10 yıl	Şirket duyuruları	SEC Form 8-K

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Buradan daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntıları Github sayfamızda mevcuttur, ayrıca raporlarımızın nasıl kullanılacağına dair kılavuzlarımız ve Youtube'da eğitimlerimiz bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları 'da mevcuttur.

Analist Kaynakları

Huadong Medicine Co., Ltd 38 Bu analistlerden 14, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

Analist	Kurum
Changming He	BOCI Research Ltd.
Ethan Cui	BofA Global Research
Shuchang Liu	Changjiang Securities Co. LTD.

Huadong Medicine Yönetim

Yönetim kriter kontrolleri 3/4

Anahtar bilgiler

Son yönetim güncellemeleri

High number of new directors

Huadong Medicine Co., Ltd, Annual General Meeting, May 08, 2024

Huadong Medicine Co., Ltd Approves Board Appointments

Huadong Medicine Co., Ltd, Annual General Meeting, Jun 01, 2022

Recent updates

An Intrinsic Calculation For Huadong Medicine Co., Ltd (SZSE:000963) Suggests It's 49% Undervalued

We Think Huadong Medicine (SZSE:000963) Can Stay On Top Of Its Debt

Investors Aren't Buying Huadong Medicine Co., Ltd's (SZSE:000963) Earnings

Third quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Huadong Medicine Co., Ltd to Report Q3, 2024 Results on Oct 25, 2024

Investor sentiment improves as stock rises 18%

There Are Reasons To Feel Uneasy About Huadong Medicine's (SZSE:000963) Returns On Capital

Huadong Medicine Co., Ltd Announces Interim Profit Distribution Plan to Be Implemented on A Shares for the Year 2024, Payable on 20 September 2024

Huadong Medicine Co., Ltd. Announces Interim Dividend for the First Half of 2024

Second quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Earnings Working Against Huadong Medicine Co., Ltd's (SZSE:000963) Share Price

Huadong Medicine Co., Ltd to Report First Half, 2024 Results on Aug 16, 2024

Huadong Medicine (SZSE:000963) Seems To Use Debt Rather Sparingly

There Are Reasons To Feel Uneasy About Huadong Medicine's (SZSE:000963) Returns On Capital

Huadong Medicine Co., Ltd Approves Cash Dividend

High number of new directors

Huadong Medicine Co., Ltd (SZSE:000963) Yearly Results Just Came Out: Here's What Analysts Are Forecasting For This Year

Huadong Medicine Co., Ltd, Annual General Meeting, May 08, 2024

Full year 2023 earnings: EPS and revenues miss analyst expectations

Market Cool On Huadong Medicine Co., Ltd's (SZSE:000963) Earnings

Huadong Medicine Co., Ltd to Report Q1, 2024 Results on Apr 26, 2024

Is Huadong Medicine (SZSE:000963) A Risky Investment?

Huadong Medicine Co., Ltd to Report Fiscal Year 2023 Results on Apr 18, 2024

Huadong Medicine's Unit, Partners to Invest in Pharmaceutical Firm

Huadong Medicine's Unit, Partners to Invest in Pharmaceutical Firm

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Huadong Medicine Co., Ltd to Report First Half, 2023 Results on Aug 16, 2023

Huadong Medicine Co., Ltd Implements Final Profit Distribution Plan of A Shares for 2022, Payable on 14 June 2023

Huadong Medicine Co., Ltd Approves Cash Dividend for 2022

Full year 2022 earnings: EPS misses analyst expectations

Price target increased to CN¥49.08

Third quarter 2022 earnings: EPS misses analyst expectations

Investor sentiment improved over the past week

Second quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Price target increased to CN¥43.06

Huadong Medicine Co., Ltd Approves Board Appointments

Huadong Medicine Co., Ltd, Annual General Meeting, Jun 01, 2022

Price target decreased to CN¥38.92

Investor sentiment improved over the past week

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Third quarter 2021 earnings released: EPS CN¥0.34 (vs CN¥0.38 in 3Q 2020)

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

Second quarter 2021 earnings released: EPS CN¥0.31 (vs CN¥0.33 in 2Q 2020)

Price target increased to CN¥45.53

Investor sentiment deteriorated over the past week

Huadong Medicine Co., Ltd Announces 2020 Final Profit Distribution Plan to Be Implemented (A Shares), Payable on 09 June 2021

Huadong Medicine Co., Ltd Announces Dividend for 2020

Investor sentiment deteriorated over the past week

Price target increased to CN¥38.24

Full year 2020 earnings released: EPS CN¥1.61 (vs CN¥1.61 in FY 2019)

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

Huadong Medicine Co., Ltd to Report Fiscal Year 2020 Results on Apr 21, 2021

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Price target raised to CN¥34.09

New 90-day low: CN¥26.05

Price target raised to CN¥33.50

Market bids up stock over the past week

New 90-day high: CN¥30.35

Third-quarter earnings released: Revenue and earnings miss expectations

Third quarter earnings released

Huadong Medicine Co., Ltd to Report Q3, 2020 Results on Oct 27, 2020

First half earnings released

Huadong Medicine Co., Ltd to Report First Half, 2020 Results on Aug 28, 2020

CEO

Görev süresi

Tazminat

Yönetim Kurulu Üyeleri